Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 underexpression
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody (1)
PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody (1)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
eribulin mesylate
Sensitive: B - Late Trials
eribulin mesylate
Sensitive
:
B
eribulin mesylate
Sensitive: B - Late Trials
eribulin mesylate
Sensitive
:
B
HER-2 underexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 underexpression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 underexpression
Gastric Cancer
HER-2 underexpression
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 underexpression
Triple Negative Breast Cancer
HER-2 underexpression
Triple Negative Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 underexpression
Gastric Adenocarcinoma
HER-2 underexpression
Gastric Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
ado-trastuzumab emtansine
Sensitive
:
C2
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
ado-trastuzumab emtansine
Sensitive
:
C2
HER-2 underexpression
Solid Tumor
HER-2 underexpression
Solid Tumor
IKS014
Sensitive: C2 – Inclusion Criteria
IKS014
Sensitive
:
C2
IKS014
Sensitive: C2 – Inclusion Criteria
IKS014
Sensitive
:
C2
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
BNT323
Sensitive: C2 – Inclusion Criteria
BNT323
Sensitive
:
C2
BNT323
Sensitive: C2 – Inclusion Criteria
BNT323
Sensitive
:
C2
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
BL-M07D1
Sensitive: C2 – Inclusion Criteria
BL-M07D1
Sensitive
:
C2
BL-M07D1
Sensitive: C2 – Inclusion Criteria
BL-M07D1
Sensitive
:
C2
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
SHR-A1811
Sensitive: C2 – Inclusion Criteria
SHR-A1811
Sensitive
:
C2
SHR-A1811
Sensitive: C2 – Inclusion Criteria
SHR-A1811
Sensitive
:
C2
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
HER-2 underexpression
Solid Tumor
HER-2 underexpression
Solid Tumor
KN046 + KN026
Sensitive: C3 – Early Trials
KN046 + KN026
Sensitive
:
C3
KN046 + KN026
Sensitive: C3 – Early Trials
KN046 + KN026
Sensitive
:
C3
HER-2 underexpression
Lung Adenocarcinoma
HER-2 underexpression
Lung Adenocarcinoma
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
trastuzumab duocarmazine
Sensitive: C3 – Early Trials
trastuzumab duocarmazine
Sensitive
:
C3
trastuzumab duocarmazine
Sensitive: C3 – Early Trials
trastuzumab duocarmazine
Sensitive
:
C3
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
trastuzumab duocarmazine
Sensitive: C3 – Early Trials
trastuzumab duocarmazine
Sensitive
:
C3
trastuzumab duocarmazine
Sensitive: C3 – Early Trials
trastuzumab duocarmazine
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
MRG002
Sensitive: C3 – Early Trials
MRG002
Sensitive
:
C3
MRG002
Sensitive: C3 – Early Trials
MRG002
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
albumin-bound paclitaxel + cyclophosphamide + epirubicin
Sensitive: C3 – Early Trials
albumin-bound paclitaxel + cyclophosphamide + epirubicin
Sensitive
:
C3
albumin-bound paclitaxel + cyclophosphamide + epirubicin
Sensitive: C3 – Early Trials
albumin-bound paclitaxel + cyclophosphamide + epirubicin
Sensitive
:
C3
HER-2 underexpression
Solid Tumor
HER-2 underexpression
Solid Tumor
BB-1701
Sensitive: C3 – Early Trials
BB-1701
Sensitive
:
C3
BB-1701
Sensitive: C3 – Early Trials
BB-1701
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
ribociclib
Sensitive
:
C3
ribociclib
Sensitive: C3 – Early Trials
ribociclib
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
BB-1701
Sensitive: C3 – Early Trials
BB-1701
Sensitive
:
C3
BB-1701
Sensitive: C3 – Early Trials
BB-1701
Sensitive
:
C3
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
HER-2 underexpression
Hormone Receptor Positive Breast Cancer
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
HER-2 underexpression
Hormone Receptor Negative Breast Cancer
HER-2 underexpression
Hormone Receptor Negative Breast Cancer
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
HER-2 underexpression
Gastric Cancer
HER-2 underexpression
Gastric Cancer
disitamab vedotin
Sensitive: C3 – Early Trials
disitamab vedotin
Sensitive
:
C3
disitamab vedotin
Sensitive: C3 – Early Trials
disitamab vedotin
Sensitive
:
C3
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy
Sensitive: C4 – Case Studies
fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy
Sensitive
:
C4
fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy
Sensitive: C4 – Case Studies
fam-trastuzumab deruxtecan-nxki + sacituzumab govitecan-hziy
Sensitive
:
C4
HER-2 underexpression
Ovarian Cancer
HER-2 underexpression
Ovarian Cancer
olaparib + niraparib + trastuzumab duocarmazine
Sensitive: D – Preclinical
olaparib + niraparib + trastuzumab duocarmazine
Sensitive
:
D
olaparib + niraparib + trastuzumab duocarmazine
Sensitive: D – Preclinical
olaparib + niraparib + trastuzumab duocarmazine
Sensitive
:
D
HER-2 underexpression
Colorectal Cancer
HER-2 underexpression
Colorectal Cancer
SAR446309
Sensitive: D – Preclinical
SAR446309
Sensitive
:
D
SAR446309
Sensitive: D – Preclinical
SAR446309
Sensitive
:
D
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
SAR443216
Sensitive: D – Preclinical
SAR443216
Sensitive
:
D
SAR443216
Sensitive: D – Preclinical
SAR443216
Sensitive
:
D
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
XMT-2056
Sensitive: D – Preclinical
XMT-2056
Sensitive
:
D
XMT-2056
Sensitive: D – Preclinical
XMT-2056
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login